Scientific article
Open access

Nitric Oxide-cGMP Pathway Modulation in an Experimental Model of Hypoxic Pulmonary Hypertension

Published inJournal of cardiovascular pharmacology and therapeutics, vol. 26, no. 6, p. 665-676
Publication date2021-11
First online date2021-05-08

Manipulation of nitric oxide (NO) may enable control of progression and treatment of pulmonary hypertension (PH). Several approaches may modulate the NO-cGMP pathway in vivo. Here, we investigate the effectiveness of 3 modulatory sites: (i) the amount of l-arginine; (ii) the size of plasma NO stores that stimulate soluble guanylate cyclase; (iii) the conversion of cGMP into inactive 5'-GMP, with respect to hypoxia, to test the effectiveness of the treatments with respect to hypoxia-induced PH. Male rats (n = 80; 10/group) maintained in normoxic (21% O2) or hypoxic chambers (10% O2) for 14 days were subdivided in 4 sub-groups: placebo, l-arginine (20 mg/ml), the NO donor molsidomine (15 mg/kg in drinking water), and phoshodiesterase-5 inhibitor sildenafil (1.4 mg/kg in 0.3 ml saline, i.p.). Hypoxia depressed homeostasis and increased erythropoiesis, heart and right ventricle hypertrophy, myocardial fibrosis and apoptosis inducing pulmonary remodeling. Stimulating anyone of the 3 mechanisms that enhance the NO-cGMP pathway helped rescuing the functional and morphological changes in the cardiopulmonary system leading to improvement, sometimes normalization, of the pressures. None of the treatments affected the observed parameters in normoxia. Thus, the 3 modulatory sites are essentially similar in enhancing the NO-cGMP pathway, thereby attenuating the hypoxia-related effects that lead to pulmonary hypertension.

  • NO-cGMP pathway
  • NO-donors
  • PDE5 inhibitors
  • Hypoxia
  • L-arginine
  • Pulmonary hypertension
  • Animals
  • Arginine / metabolism
  • Cyclic GMP / metabolism
  • Hypertension, Pulmonary / drug therapy
  • Hypertension, Pulmonary / physiopathology
  • Hypoxia / drug therapy
  • Hypoxia / physiopathology
  • Male
  • Myocardium / pathology
  • Nitric Oxide / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Sildenafil Citrate / pharmacology
  • Vasodilator Agents
Citation (ISO format)
REINERO, Melanie et al. Nitric Oxide-cGMP Pathway Modulation in an Experimental Model of Hypoxic Pulmonary Hypertension. In: Journal of cardiovascular pharmacology and therapeutics, 2021, vol. 26, n° 6, p. 665–676. doi: 10.1177/10742484211014162
Main files (1)
Article (Published version)
ISSN of the journal1074-2484

Technical informations

Creation09/09/2022 12:53:41 PM
First validation05/02/2023 4:30:14 PM
Update time05/02/2023 4:30:14 PM
Status update05/02/2023 4:30:14 PM
Last indexation05/06/2024 3:47:51 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack